Factors associated with willingness to be part of a research study on Pre-exposure Prophylaxis for HIV prevention (N = 1393).

<p>OR = odds ratio; AOR = adjusted odds-ratio; 95% CI = 95% confidence interval.</p>*<p>UAI with 2 or more partners, UAI with casual partners, and/or UAI with unknown/discordant partners in the previous 12 months.</p>†<p>HIV treatment optimism – ‘I am less worried about HIV infection now that treatments have improved’.</p

Factors associated with Awareness of Pre-exposure Prophylaxis for HIV prevention (N = 1393).

<p>OR = odds ratio; AOR = adjusted odds-ratio; 95% CI = 95% confidence interval.</p>*<p>UAI with 2 or more partners, UAI with casual partners, and/or UAI with unknown/discordant partners in the previous 12 months.</p>†<p>HIV treatment optimism 1– ‘I am less worried about HIV infection now that treatments have improved’.</p

Factors associated with likelihood of using Pre-exposure Prophylaxis for HIV prevention (N = 1393).

<p>OR = odds ratio; AOR = adjusted odds-ratio; 95% CI = 95% confidence interval.</p>*<p>UAI with 2 or more partners, UAI with casual partners, and/or UAI with unknown/discordant partners in the previous 12 months.</p>†<p>HIV treatment optimism – ‘I am less worried about HIV infection now that treatments have improved’.</p

HIV infection status and sexual health testing behaviour of MSM who answered the questionnaire and provided an oral fluid specimen (N = 1217), 2011.

<p>*Fisher's Exact test.</p

Sample Characteristics (N = 1393).

*<p>UAI with 2 or more partners, UAI with casual partners, and/or UAI with unknown/discordant partners in the previous 12 months.</p>†<p>HIV treatment optimism – ‘I am less worried about HIV infection now that treatments have improved’.</p

HIV status by demographic characteristics and behavioural risk factors of MSM who answered the questionnaire and provided an oral fluid specimen (N = 1217), 2011.

<p>HIV status by demographic characteristics and behavioural risk factors of MSM who answered the questionnaire and provided an oral fluid specimen (N = 1217), 2011.</p

HIV prevalence, self-reported HIV status, HIV and sexually transmitted infection testing behaviour among MSM providing an oral fluid specimen across the survey years 2005, 2008 and 2011.

<p>*Adjusted for age, qualification level, employment status and frequency of gay scene use, which differed between the surveys.</p

Supplemental Material - Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function

Supplemental Material for Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function by Caoilfhionn M Connolly, Jessica Li, Daniel Goldman, Andrea Fava, Laurence Magder, and Michelle Petri in Lupus</p

Daily Local-Level Estimates of Ambient Wildfire Smoke PM_2.5 for the Contiguous US

Smoke from wildfires is a growing health risk across the US. Understanding the spatial and temporal patterns of such exposure and its population health impacts requires separating smoke-driven pollutants from non-smoke pollutants and a long time series to quantify patterns and measure health impacts. We develop a parsimonious and accurate machine learning model of daily wildfire-driven PM2.5 concentrations using a combination of ground, satellite, and reanalysis data sources that are easy to update. We apply our model across the contiguous US from 2006 to 2020, generating daily estimates of smoke PM2.5 over a 10 km-by-10 km grid and use these data to characterize levels and trends in smoke PM2.5. Smoke contributions to daily PM2.5 concentrations have increased by up to 5 μg/m3 in the Western US over the last decade, reversing decades of policy-driven improvements in overall air quality, with concentrations growing fastest for higher income populations and predominantly Hispanic populations. The number of people in locations with at least 1 day of smoke PM2.5 above 100 μg/m3 per year has increased 27-fold over the last decade, including nearly 25 million people in 2020 alone. Our data set can bolster efforts to comprehensively understand the drivers and societal impacts of trends and extremes in wildfire smoke

Supplementary Figure 2 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

PDF file, 72K, Binding experiments were carried out by surface plasmon resonance (SPR) measurements on a ProteOn XPR36 (Bio-Rad Laboratories) instrument at 25{degree sign}C. For the binding competition experiment, PlGF (20μg/ml) was immobilized at high surface densities (3000-4000 RU) on an activated ProteOn GLC sensor chip using standard amine coupling procedures as described by the manufacturer. Analytes (Nrp1, Anti-Nrp1B) and 1:1 molar ratio mixture of analytes (Nrp1 + Anti-Nrp1B) were injected in phosphate-buffered saline (PBS), 0.005% v/v Tween-20 (pH7.4) at a flow rate of 100μl/min and sensorgrams for association and disassociation phases were recorded. Analytes were injected for 150 s and allowed to disassociate for 450 s. Data was processed with the ProteOn Manager software (version 2.0, Bio-Rad).</p